MOTS-c is a 16-amino acid peptide encoded in mitochondrial DNA — the only known peptide of mitochondrial origin. It was first characterized in research published in Cell in 2015. MOTS-c is not FDA-approved as a standalone drug. TruVera provides MOTS-c through licensed compounding pharmacies under Section 503A of the Federal Food, Drug, and Cosmetic Act — available only with a valid prescription from a licensed clinician.

AMPK (AMP-activated protein kinase) is often described as the body's master metabolic switch. When activated, it signals cells to shift into an energy-efficient mode: increasing glucose uptake into muscle cells (via GLUT4 translocation), enhancing fat burning, promoting mitochondrial function, and reducing processes that consume energy without benefit. Practically, AMPK activation is associated with improved blood sugar regulation, better body composition, enhanced exercise endurance, and metabolic effects that parallel many benefits of sustained aerobic exercise.

MOTS-c is most commonly administered as a subcutaneous injection, typically several times per week, because peptides of this size are not reliably absorbed orally. Your clinician will specify the dose, injection frequency, and protocol duration based on your metabolic goals and health history. Detailed injection instructions are provided with your medication.

Initial improvements in energy and exercise tolerance are often reported within 4–6 weeks. More measurable metabolic changes — including shifts in fasting glucose, insulin sensitivity markers, or body composition — are typically observed over 8–12 weeks of consistent use. Individual responses vary based on baseline metabolic health, diet, activity level, and dosing protocol. Your clinician will evaluate your progress at regular check-ins.

MOTS-c is generally considered well tolerated in research to date. The most commonly reported effects are injection-site reactions — mild redness, swelling, or discomfort at the injection site that typically resolves within hours. Systemic side effects have not been prominently reported in preclinical models. As a compounded peptide without completed large-scale human trials, long-term safety data in humans remains limited. Your clinician will review your full health history, current medications, and any contraindications before prescribing.

Yes. You can pause or cancel at any time through your TruVera patient portal — no phone calls, no cancellation fees. If you have questions about your protocol before canceling, your care team is always available to discuss adjustments or alternative approaches.